Publication: 2533

Publication: 2533

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

URL

Google Scholar

Citation:

Meeting Instance:: ESMO 2016
Year:: 2016
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:

Note:

Methodological:: No
Biospecimen:: No
SDC:: Yes

Parents:: None
Children:: 2604

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882

Corr. Author:
Authors:: Toni K. Choueiri Susan Halabi Ben L. Sanford Olwen Hahn M. Dror Michaelson Meghara Walsh Thomas Olencki Joel Picus Eric J. Small Daniel George Shaker Dahkil Michael J. Morris

Networks:: CA824, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007

Study: Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: